Health & bio
A2 Bio's A2B543 autologous CAR-T earns Fast Track for MSLN-positive solid tumors
A2 Biotherapeutics announced April 1 that A2B543, an autologous CAR-T candidate, gained FDA Fast Track for relapsed/locally advanced/metastatic MSLN-expressing solid tumors in HLA-A*02-compatible adults.
Primary sources · 1